Find Locations
For hours, walk-ins and appointments.Special Instructions
Provide a copy of the pathology report; the NRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363.
Expected Turnaround Time
5 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Formalin-fixed, paraffin-embedded (FFPE) tissue or slides.
Volume
Formalin-fixed, paraffin-embedded tissue block or four unstained slides and one matching H&E-stained slide at 5 μM.
Minimum Volume
Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4mm² and ≥50% tumor content are preferred.
Container
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides
Storage Instructions
Maintain blocks/slides at room temperature.
Causes for Rejection
Tumor block containing insufficient tumor tissue; broken or stained slides
Test Details
Use
NRAS is a guanosine triphosphate (GTP)-binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival, and differentiation. Mutations in the NRAS oncogene are frequently found in human cancers. They are common in melanomas, colorectal cancer, and thyroid cancer. This assay detects NRAS mutations in exons 2, 3, and 4, allowing the determination of drug response.
Limitations
This assay is able to detect 5% mutation in a background of wild-type DNA. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Methodology
SNaPshot Multiplex PCR (primer extension-based method)
References
Bae JS, Choi SK, Jeon S, et al. Impact of NRAS mutations on the diagnosis of follicular neoplasm of thyroid. Int J Endocrinol. 2014:289834. 25254041
Benson AB 3rd, Bekaii-Saab T Chan E, et al. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 1; 10(12):1528-1564. 23221790
Benson AB 3rd, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-1059. 24994923
Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer. Pooled analysis of the CRYSTAL and OPUS randomized clinical trials. Eur J Cancer. 2012 Jul; 48(10):1466-1475. 22446022
Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol. 2010 Nov 1; 28(31):4697-4705. 20921465
Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014 Mar 4; 13:45-54. 24588908
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 481120 | NRAS Extended Analysis | 481121 | Results: | 21719-0 | ||
| 481120 | NRAS Extended Analysis | 481122 | Indications: | 42349-1 | ||
| 481120 | NRAS Extended Analysis | 481123 | Specimen Location: | N/A | ||
| 481120 | NRAS Extended Analysis | 481124 | Specimen Type: | 31208-2 | ||
| 481120 | NRAS Extended Analysis | 481125 | Block Number: | 57723-9 | ||
| 481120 | NRAS Extended Analysis | 481088 | Nucleotide Change: | 48004-6 | ||
| 481120 | NRAS Extended Analysis | 481089 | Amino Acid Change: | 48005-3 | ||
| 481120 | NRAS Extended Analysis | 481126 | Background: | 8251-1 | ||
| 481120 | NRAS Extended Analysis | 481127 | Methodology: | 49549-9 | ||
| 481120 | NRAS Extended Analysis | 481128 | References: | 75608-0 | ||
| 481120 | NRAS Extended Analysis | 481131 | Director Review: | 72486-4 | ||
| 481120 | NRAS Extended Analysis | 480903 | Microdissection Performed | 8100-0 | ||
| 481120 | NRAS Extended Analysis | 481146 | Referring Physician | 18781-5 | ||
| 481120 | NRAS Extended Analysis | 481147 | Treating Physician | 18781-5 | ||
| 481120 | NRAS Extended Analysis | 481148 | Body Site | 39111-0 | ||
| 481120 | NRAS Extended Analysis | 481149 | Client Specimen ID | N/A | ||
| 481120 | NRAS Extended Analysis | 481150 | Specimens Received | 31208-2 | ||
| 481120 | NRAS Extended Analysis | 481151 | Clinical Data | 55752-0 | ||
| 481120 | NRAS Extended Analysis | 481153 | Interpretation | 62365-2 | ||
| 481120 | NRAS Extended Analysis | 481154 | Analytical Results | 21719-0 | ||
| 481120 | NRAS Extended Analysis | 481155 | Comments | 77202-0 | ||
| 481120 | NRAS Extended Analysis | 481157 | Signed By | 19139-5 | ||
| 481120 | NRAS Extended Analysis | 481158 | Disclaimers | N/A | ||
| 481120 | NRAS Extended Analysis | 481159 | 51969-4 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf